InspireMD (NYSE:NSPR) Research Coverage Started at StockNews.com

Posted by Defense World Staff on Jun 11th, 2024

Equities research analysts at StockNews.com started coverage on shares of InspireMD (NYSE:NSPR – Get Free Report) in a research report issued on Tuesday. The firm set a “sell” rating on the stock.

InspireMD Stock Performance

Shares of NSPR stock opened at $2.66 on Tuesday. The stock has a fifty day moving average price of $2.29 and a 200 day moving average price of $2.49. The stock has a market cap of $66.30 million, a PE ratio of -3.50 and a beta of 0.95. InspireMD has a 1 year low of $1.76 and a 1 year high of $3.85.

InspireMD (NYSE:NSPR – Get Free Report) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.06). InspireMD had a negative return on equity of 55.12% and a negative net margin of 350.35%. The company had revenue of $1.51 million during the quarter, compared to analyst estimates of $1.38 million. During the same period last year, the firm earned ($0.53) earnings per share. As a group, equities research analysts predict that InspireMD will post -0.82 earnings per share for the current year.

Institutional Investors Weigh In On InspireMD

A hedge fund recently bought a new stake in InspireMD stock. McKinley Carter Wealth Services Inc. purchased a new position in InspireMD, Inc. (NYSE:NSPR – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 10,000 shares of the company’s stock, valued at approximately $28,000. Hedge funds and other institutional investors own 44.78% of the company’s stock.

About InspireMD

(Get Free Report)

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.